Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XLO
stocks logo

XLO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
10.90M
+532.25%
-0.070
-65%
6.90M
+135.49%
-0.105
-41.67%
6.00M
-25.78%
-0.105
-34.38%
Estimates Revision
The market is revising No Change the revenue expectations for Xilio Therapeutics, Inc. (XLO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 5.89%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+5.89%
In Past 3 Month
Wall Street analysts forecast XLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLO is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast XLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLO is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.741
sliders
Low
2.00
Averages
2.00
High
2.00
Current: 0.741
sliders
Low
2.00
Averages
2.00
High
2.00
Leerink
Outperform
initiated
$72
2025-08-06
Reason
Leerink
Price Target
$72
2025-08-06
initiated
Outperform
Reason
Leerink initiated coverage of Xilio Therapeutics with an Outperform rating and $72 price target. The company's lead program vilastobart, a conditionally masked CTLA-4 antagonist, has shown proof-of-concept efficacy in relapsed / refractory microsatellite stable non-liver metastatic colorectal cancer, a large indication, the analyst tells investors in a research note. The firm believes Xilio is among the industry leaders of developing protease-masked biologics.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Xilio Therapeutics Inc (XLO.O) is -1.92, compared to its 5-year average forward P/E of -1.40. For a more detailed relative valuation and DCF analysis to assess Xilio Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.40
Current PE
-1.92
Overvalued PE
-0.28
Undervalued PE
-2.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.53
Undervalued EV/EBITDA
-1.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.19
Current PS
0.00
Overvalued PS
2.97
Undervalued PS
-0.59
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XLO News & Events

Events Timeline

(ET)
2025-11-13
07:35:15
Xilio Therapeutics anticipates sufficient cash to support operations through the first quarter of 2027.
select
2025-11-13
07:34:59
Xilio Therapeutics announces Q3 earnings per share of 11 cents, compared to a loss of 22 cents in the previous year.
select
2025-11-07 (ET)
2025-11-07
09:17:48
Xilio Therapeutics reveals updated findings from Phase 2 trial of vilastobart
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-13NASDAQ.COM
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.

  • Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.

  • Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.

[object Object]
Preview
9.0
11-07Newsfilter
Xilio Therapeutics Unveils Late-Breaking Phase 2 Results for Vilastobart in MSS mCRC Patients with Elevated Plasma Tumor Mutational Burden at the 40th Annual SITC Meeting

  • Clinical Trial Results: Xilio Therapeutics reported a 40% objective response rate (ORR) in heavily pre-treated patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without liver metastases and high plasma tumor mutational burden (TMB) in their Phase 2 trial of vilastobart combined with atezolizumab.

  • Plasma TMB as a Biomarker: Approximately 55% of patients with MSS CRC are estimated to have high plasma TMB, indicating a significant population that may benefit from the combination treatment, highlighting the potential of plasma-based TMB as a predictive biomarker for response.

  • Safety Profile: The combination therapy of vilastobart and atezolizumab demonstrated a well-tolerated safety profile, with most treatment-related adverse events being Grade 1 or 2, and only a small percentage of patients discontinuing treatment due to adverse effects.

  • Future Plans: Xilio is seeking partnerships to further develop vilastobart in combination with PD-(L)1 or PD1-VEGF therapies for MSS CRC and other tumor types, following the promising results from the clinical trial.

[object Object]
Preview
9.0
10-30Newsfilter
Xilio Therapeutics to Showcase Phase 2 Data on Vilastobart's Response Rate in MSS mCRC Patients with High Plasma Tumor Mutational Burden in Late-Breaking Presentation at SITC 40th Annual Meeting

  • Xilio Therapeutics Presentation: Xilio Therapeutics will present a late-breaking poster on vilastobart, an anti-CTLA-4 therapy, at the SITC 40th Annual Meeting from November 5-9, 2025, focusing on its efficacy in metastatic colorectal cancer patients with high plasma tumor mutational burden.

  • Poster Details: The poster, titled "Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab," will be presented on November 7, 2025, and will be available on Xilio's website.

  • Company Overview: Xilio Therapeutics is a clinical-stage biotechnology firm developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects.

  • Forward-Looking Statements: The press release includes cautionary notes regarding forward-looking statements, highlighting potential risks and uncertainties related to Xilio's clinical programs and business operations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Xilio Therapeutics Inc (XLO) stock price today?

The current price of XLO is 0.741 USD — it has increased 4.96 % in the last trading day.

arrow icon

What is Xilio Therapeutics Inc (XLO)'s business?

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.

arrow icon

What is the price predicton of XLO Stock?

Wall Street analysts forecast XLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLO is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Xilio Therapeutics Inc (XLO)'s revenue for the last quarter?

Xilio Therapeutics Inc revenue for the last quarter amounts to 19.07M USD, increased 742.51 % YoY.

arrow icon

What is Xilio Therapeutics Inc (XLO)'s earnings per share (EPS) for the last quarter?

Xilio Therapeutics Inc. EPS for the last quarter amounts to -0.11 USD, decreased -50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Xilio Therapeutics Inc (XLO)'s fundamentals?

The market is revising No Change the revenue expectations for Xilio Therapeutics, Inc. (XLO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 5.89%.
arrow icon

How many employees does Xilio Therapeutics Inc (XLO). have?

Xilio Therapeutics Inc (XLO) has 64 emplpoyees as of December 05 2025.

arrow icon

What is Xilio Therapeutics Inc (XLO) market cap?

Today XLO has the market capitalization of 38.89M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free